Arkolith/Insider Trading/KPTI/Form 4

Poulton Stuart

EVP, Chief Development OfficerKaryopharm Therapeutics Inc. (KPTI) · full profile →Form 4 · filed Mar 4, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 28, 2025Grant(A)5K—$026K
Feb 28, 2025Grant(A)5K—$031K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 28, 2025Grant(A)9K—$09K
Feb 28, 2025Grant(A)10K—$010K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-032309) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML